Hybrid drugs are new, proprietary pharma assets, that combine software with drugs to create SaMD - Drug combinations. Digital interventions target main disease endpoints as well as comorbidities and side effect, bringing integrative medicine to the patient. Combining therapeutic software interventions with pharmacological treatment facilitates personalized treatment at scale, based on real world data.
